2025年4月9日 星期三
首页        期刊介绍        编委会        投稿指南        期刊订阅        广告合作        联系我们        English
河北医学  2018, Vol. 24 Issue (9): 1420-1423    DOI: 10.3969/j.issn.1006-6233.2018.09.004
  论著 本期目录 | 过刊浏览 | 高级检索 |
通心络胶囊联合厄贝沙坦对早期糖尿病肾病的疗效及血清CysC IL-18 ET-1 NO水平的影响
魏洪发, 宁洁, 冯小玲
广东省深圳市龙华区中心医院, 广东 深圳 518110
Effect of Tongxinluo Capsule combined with Irbesartan on Early Diabetic Nephropathy and Serum Levels of CysC IL-18 ET-1 and NO
WEI Hongfa, NING Jie, FENG Xiaoling
The Central Hospital in Longhua District of Shenzhen, Guangdong Shenzhen 518110, China
全文: PDF (1346 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的: 探讨通心络胶囊联合厄贝沙坦(Irb)治疗早期糖尿病肾病(DKD)的临床效果及对患者血清胱抑素C(CysC)、白细胞介素(IL)-18、内皮素(ET)-1、一氧化氮(NO)水平的影响。 方法: 选取我院2015年1月至2017年1月收治的138例早期DKD患者,采取随机数字表法均分为两组。对照组给予Irb治疗,观察组采取通心络胶囊联合Irb治疗。记录比较两组临床疗效,治疗前后血清CysC、IL-18、ET-1、NO水平的变化及不良反应的发生情况。 结果: 治疗12周后,观察组总有效率较对照组明显升高(P<0.05)。与治疗前对比,两组治疗12周后血清CysC、IL-18、ET-1水平均显著下降(P<0.01),NO水平均显著升高(P<0.01),且观察组血清CysC、IL-18、ET-1水平显著低于对照组,NO水平明显高于对照组(P<0.01)。两组不良反应发生率比较差异无统计学意义(P>0.05)。 结论: 通心络胶囊联合厄贝沙坦治疗早期DKD能有效提高其临床疗效,改善肾功能,且安全性高,可能与其显著降低患者血清CysC、IL-18、ET-1水平,提高血清NO水平,进而改善机体微炎症状态及血管内皮功能有关。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
魏洪发
宁洁
冯小玲
关键词 早期糖尿病肾病 通心络胶囊 厄贝沙坦    
AbstractObjective: To investigate the clinical efficacy of tongxinluo capsule combined with irbesartan (Irb) in the treatment of early diabetic kidney disease (DKD) and the effect on the serum cystatin C (CysC), interleukin (IL)-18, endothelin (ET)-1 and nitric oxide (NO) levels. Methods: 138 cases of patients with early DKD admitted in our hospital from Jan. 2015 to Jan. 2017 were selected and divided into two groups on a random basis. The control group was treated with Irb, while the observation group was administrated with tongxinluo capsule in combination with Irb. The clinical efficacy, changes of serum CysC, IL-18, ET-1, NO levels before and after treatment and occurrence of adverse reactions were compared between the two groups. Results: After 12 weeks of treatment, the total effective rate of the observation group was significantly higher than that of the control group (P<0.05). Compared with those before treatment, the serum CysC, IL-18 and ET-1 levels of both groups at 12 weeks after treatment were remarkably decreased(P<0.01), while the NO levels of both groups at 12 weeks after treatment were remarkably increased (P< 0.01). The serum CysC, IL-18 and ET-1 levels of observation group were significantly lower, while the serum NO level was much higher than those of the control group(P<0.01). There was no statistic difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The combination of Tongxinluo capsule and erbesartan in the treatment of early DKD can effectively improve its clinical efficacy and improve renal function with high safety. It may significantly reduce the level of serum CysC, IL-18, ET-1, increase the level of serum NO, and then improve the microinflammatory state and vascular endothelial function of the body.
Key wordsEarly diabetic kidney disease    Tongxinluo capsule    Irbesartan
    
基金资助:广东省自然科学基金资助项目,(编号:2011CJ232)
通讯作者: 冯小玲   
引用本文:   
魏洪发, 宁洁, 冯小玲. 通心络胶囊联合厄贝沙坦对早期糖尿病肾病的疗效及血清CysC IL-18 ET-1 NO水平的影响[J]. 河北医学, 2018, 24(9): 1420-1423.
WEI Hongfa, NING Jie, FENG Xiaoling. Effect of Tongxinluo Capsule combined with Irbesartan on Early Diabetic Nephropathy and Serum Levels of CysC IL-18 ET-1 and NO. HeBei Med, 2018, 24(9): 1420-1423.
链接本文:  
http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2018.09.004     或     http://www.hbyxzzs.cn/CN/Y2018/V24/I9/1420
冀ICP备2025106803号    冀公网安备13080202000786号
版权所有 © 2016 《河北医学》杂志社
本系统由北京玛格泰克科技发展有限公司设计开发